What are the treatment options for atopic eczema (atopic dermatitis)?

Treatment of Asteatotic Eczema (Atopic Dermatitis)

For adults with atopic dermatitis, start with optimized topical therapy (corticosteroids, calcineurin inhibitors, or newer agents like roflumilast or tapinarof), and if inadequate control persists, advance to systemic therapy with dupilumab as the first-line systemic agent, followed by other biologics or JAK inhibitors for refractory cases 1, 2.

Stepwise Treatment Algorithm

Step 1: Foundation - Basic Management for All Patients

• Consistent moisturization is essential for all severity levels and helps prevent flares 3, 4
• Use soap substitutes and bath oils universally 4
• Identify and avoid trigger factors where possible 4
• Provide therapeutic patient education about disease recognition and medication use 3

Step 2: Topical Anti-Inflammatory Therapy (First-Line)

Topical corticosteroids (TCS) remain the primary treatment for active inflammation 3, 5:

• Select potency based on anatomic site (lower potency for face/intertriginous areas, higher for trunk/extremities)
• Despite excellent safety profiles, address steroid phobia proactively to ensure adherence 3

Alternative topical agents when TCS are insufficient or inappropriate:

• Topical calcineurin inhibitors (tacrolimus, pimecrolimus) for sensitive sites like the face 4, 6
• Newer nonsteroidal options with strong recommendations 1:
  • Roflumilast cream (PDE-4 inhibitor) - approved for adults and children ≥6 years 7
  • Tapinarof cream - approved for adults and children ≥2 years 1, 7
  • Ruxolitinib cream (topical JAK1/JAK2 inhibitor) - significantly improves outcomes with low systemic toxicity concern 8
  • Delgocitinib and difamilast ointments 9

Step 3: Adjunctive Therapies During Flares

• Wet-wrap therapy and bleach baths may help selected patients, though evidence is inconsistent 3
• Antihistamines are no longer routinely recommended 3
• Consider alternative diagnoses (contact dermatitis, cutaneous lymphoma) if optimized topical therapy fails 2

Step 4: Systemic Therapy for Moderate-to-Severe Disease

When topical therapy proves inadequate, the 2025 AAD guidelines provide clear hierarchy:

First-Line Systemic Agent: Dupilumab

Dupilumab is universally favored as the first-line systemic therapy 2:

• IL-4/IL-13 pathway blocker with excellent safety track record over 5+ years
• Dosing: 600 mg subcutaneous loading dose, then 300 mg every 2 weeks
• Approved for patients ≥6 months old 7
• Strong recommendation based on large RCTs including 52-week data 2

Alternative Biologics with Strong Recommendations:

• Tralokinumab (IL-13 blocker) - approved for ages ≥12 years, somewhat less effective than dupilumab at 16 weeks 2, 7
• Lebrikizumab (IL-13 blocker) - strong recommendation with concomitant topical therapy 1
• Nemolizumab (IL-31 receptor blocker) - targets nonhistaminergic itch specifically, approved for ages ≥12 years with strong recommendation when used with topical therapy 1, 9, 7

Oral JAK Inhibitors with Strong Recommendations:

• Abrocitinib, baricitinib, and upadacitinib all have strong recommendations 2
• May have better efficacy than dupilumab based on indirect comparisons, but require closer monitoring for adverse events 6
• FDA labeling indicates use only after failure of other systemic agents including biologics, though clinical judgment may vary 6
• Approved for ages ≥12 years in the US (baricitinib approved in Europe/Japan but not US for AD) 7

Step 5: Traditional Immunosuppressants (Conditional Recommendations)

Phototherapy (narrowband UVB) should be considered before traditional systemic agents 2, 6:

• Conditional recommendation in favor
• Specialist consultation recommended 4

Traditional immunosuppressants have conditional recommendations 2:

• Cyclosporine - preferred for acute flares and first-line among traditional agents 6
• Methotrexate and azathioprine - equal secondary choices 6
• Mycophenolate - conditional recommendation

Systemic corticosteroids receive a conditional recommendation AGAINST use 2 - avoid for chronic management despite potential use in acute severe flares.

Critical Clinical Pitfalls

1. Don't delay systemic therapy in truly refractory moderate-to-severe disease - biologics and JAK inhibitors should be considered before traditional immunosuppressants given superior safety profiles 6

2. Address steroid phobia explicitly - TCS side effects are infrequent, but fear prevents adherence 3

3. Recognize that not all AD patients have allergies - avoid unnecessary extensive allergy testing 4

4. Maintain topical therapy even when starting systemic agents - topicals can be used concurrently for maintenance, rescue, or flare treatment 2

Evidence Quality Considerations

The 2025 AAD focused update 1 represents the most current guidance, adding strong recommendations for four new agents (tapinarof, roflumilast, lebrikizumab, nemolizumab). However, most RCTs are short-duration, limiting long-term comparative conclusions 1, 2. The consistent limitation across all guidelines is that extension studies don't provide robust head-to-head long-term data, making real-world clinical experience increasingly important for treatment sequencing decisions.